Search
Search Results
##search.searchResults.foundPlural##
-
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
2719PDF: 971HTML: 5494 -
ANTIFUNGAL THERAPY IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS
4629PDF: 1504HTML: 2224Untitled: 187Untitled: 202Untitled: 209Untitled: 191Untitled: 187 -
PEDIATRIC HODGKIN LYMPHOMA IN LOW- and MIDDLE-INCOME COUNTRIES (LMICs). A NARRATIVE REVIEW Pediatric Hodgkin's lymphoma in low-income countries
1184PDF: 798HTML: 254 -
THE HISTORY OF DEFERIPRONE (L1) AND THE COMPLETE TREATMENT OF IRON OVERLOAD IN THALASSAEMIA The history and roles of deferiprone
2216PDF: 1537HTML: 570 -
PROGNOSTIC FACTORS IN HODGKIN LYMPHOMA
3162PDF: 1907HTML: 7450 -
CAR-T CELL THERAPY IN LARGE B CELL LYMPHOMA CAR-T; Large B Cell Lymphoma; Salvage Therapy,
3525PDF: 1357HTML: 166 -
THE EVOLVING ROLE OF RADIOTHERAPY IN EARLY STAGE HODGKIN’S LYMPHOMA
2135PDF: 914HTML: 6766Figure 1: 154 -
ESCHERICHIA COLI: AN IMPORTANT PATHOGEN IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES
1752PDF: 686HTML: 2082Untitled: 186Untitled: 137Untitled: 151Untitled: 138Untitled: 144Untitled: 160Untitled: 166 -
CMV IN HEMATOPOIETIC STEM CELL TRANSPLANTATION
4684PDF: 1702HTML: 2685Untitled: 188 -
FDG-PET SCAN: A NEW PARADIGM FOR FOLLICULAR LYMPHOMA MANAGEMENT.
3228PDF: 1205HTML: 2170 -
Guest Editor: Pellegrino Musto BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA: APPROPRIATE SELECTION OF PATIENTS AND SEQUENCING BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA
1415PDF: 1110HTML: 168 -
BACTERIAL INFECTIONS IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS
2992PDF: 1760HTML: 3534 -
PREVENTION OF ? THALASSEMIA IN NORTHERN ISRAEL - A COST-BENEFIT ANALYSIS.
2396PDF: 1113HTML: 11770 -
THALIDOMIDE AMELIORATES ERYTHROPOIESIS AND IRON HOMEOSTASIS IN TRANSFUSION-DEPENDENT β-THALASSEMIA Thalidomide ameliorates erythropoiesis and iron homeostasis
1288PDF: 1366PDF: 985HTML: 185 -
MEDICAL TREATMENT OF HEPATOCELLULAR CARCINOMA
700PDF: 452HTML: 6243 -
AUTOIMMUNE CYTOPENIAS IN CHRONIC LYMPHOCYTIC LEUKEMIA, FACTS AND MYTHS
2095PDF: 1151HTML: 3669 -
APPROPRIATE DURATION OF INTRAVENOUS TREATMENT OF CANDIDEMIA AND TIMING OF STEP DOWN TO ORAL THERAPY IN NON-NEUTROPENIC PATIENTS
2691PDF: 884HTML: 339Preferred Reviewers: 186 -
PARASITIC INFECTIONS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION
3613PDF: 1199HTML: 3861Untitled: 181Untitled: 240 -
The MINI-POLATUZUMAB VEDOTINE PLUS CHP (POLA-R-CHP) VS. MINI-R-CHOP IN PATIENTS OVER 80 YEARS OF AGE WITH DIFFUSE LARGE B-CELL LYMPHOMA: A RETROSPECTIVE, PROPENSITY SCORE-MATCHED ANALYSIS STRATIFIED BY SIMPLIFIED FRAILTY SCORE PolaRCHP vs. RCHOP for older patients
881PDF: 321HTML: 74 -
SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML
3486PDF: 830HTML: 6692 -
IS THERE A ROLE FOR MINIMAL RESIDUAL DISEASE MONITORING IN FOLLICULAR LYMPHOMA IN THE CHEMO-IMMUNOTHERAPY ERA?
3291PDF: 1239HTML: 2187Fi.1 Gritti.Rambaldi: 182 -
THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION
3951PDF: 1851HTML: 1740 -
SOLITARY PLASMACYTOMA
3734PDF: 2124HTML: 1186fIGURES 1,2: 186 -
THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA
2388PDF: 753HTML: 1718







